LL-37 peptide: antimicrobial promise vs. biohacking hype

What did @.dr.sim.bhatti actually say?

The creator, identifying as a board-certified internal medicine, hematology, and medical oncology physician, argued that LL-37 should not be used systemically or as a subcutaneous injection. The core claims: LL-37 has "a direct link to accelerated cardiovascular disease" and "a direct link with the development of certain autoimmune conditions including lupus." They also said the only appropriate use is topical application for chronic non-healing wounds, and that measuring your baseline LL-37 levels is not possible through any commercially available lab. They closed by suggesting thymosin alpha-1 as a safer immune-support alternative, with a carve-out for people with pre-existing autoimmune disease.

That is a fairly conservative and safety-oriented take on a peptide that the biohacking community has been aggressively promoting. Credit where it is due: they led with risk, not hype.

Does the science back this up?

Partly, yes. The cardiovascular and autoimmune associations are real, but calling them a "direct link" oversimplifies a complicated body of preclinical and observational data. The word "direct" implies a cleaner causal chain than the evidence currently supports.

LL-37 is a human cathelicidin antimicrobial peptide, part of your innate immune system. Research has shown it plays a role in atherosclerosis, though the story is not straightforward. Döring et al. (2012, European Heart Journal) found that LL-37 promotes platelet aggregation and thrombosis in mouse models, which is legitimately concerning. However, other work suggests LL-37 has context-dependent effects, sometimes acting as an anti-inflammatory and sometimes driving inflammation depending on concentration and tissue environment (Vandamme et al., 2012, Cellular and Molecular Life Sciences).

On the lupus connection, the evidence is more solid. Lande et al. (2011, Science Translational Medicine) showed that LL-37 can form complexes with self-DNA, activating plasmacytoid dendritic cells and driving type I interferon responses, a mechanism implicated in lupus pathogenesis. That is not trivial. But again, this is endogenous dysregulation data, not data from exogenous supplementation.

What did they get wrong (or right)?

They got the general direction right but leaned on the word "direct" too hard. There are no published human trials on exogenous systemic LL-37 supplementation driving cardiovascular disease or lupus onset. The risks are inferred from mechanistic studies and observations about dysregulated endogenous LL-37, which is a reasonable extrapolation but not a proven fact for injected peptide use.

The claim that LL-37 deficiency cannot be measured by any commercially available lab is mostly accurate. LL-37 is not a standard clinical panel. Some research labs offer it, but clinical standardization is essentially nonexistent, and there are no validated reference ranges for guiding supplementation decisions. That is a fair and useful point.

The topical wound-healing application is supported by real data. Steinstraesser et al. (2012, PLOS ONE) demonstrated LL-37 accelerates wound closure in diabetic wound models, and there are early-phase clinical efforts looking at topical formulations. That specific use case has more grounding than systemic administration.

The thymosin alpha-1 recommendation is reasonable but comes with its own limitations. The caveat about autoimmune disease is correct: thymosin alpha-1 is an immune modulator, and its effects in autoimmune contexts are not reliably predictable from available data.

What should you actually know?

If you are seeing LL-37 promoted in biohacking communities as an immune booster or infection fighter via injection, the caution in this video is warranted. The peptide is not inert, and the biology around it is complex enough that systemic self-administration is a genuinely poor idea given what we currently know.

LL-37 is not approved by the FDA for any therapeutic use. There are no completed Phase III human trials on exogenous LL-37 administration. Most of the data comes from in vitro work, animal models, and observations of people with elevated or depleted endogenous levels due to disease states. Extrapolating that to injection protocols is a significant leap.

The cardiovascular and autoimmune signals are real enough to treat seriously. Until human clinical trial data exists for exogenous systemic LL-37, the risk-benefit math does not favor injecting it for general immune optimization. Topical use for specific wound-care indications remains the only context with any meaningful evidence base, and even there, clinical guidance from a qualified physician is necessary.